Axinn partner Chad Landmon and associates Aaron Savit and Ian Swan co-authored the article "Chevron Deference on the Brink: Small Fish May Mean Big Changes for FDA," published in the Spring 2024 issue of the Food and Drug Law Institute's Update magazine.

Click here to access the article. Shared with the permission of FDLI.

Click here to access the Spring 2024 issue of Update magazine. 

^{*Not yet admitted to the Washington, DC Bar.}